ARYx Therapeutics Appoints Former Amgen Exec to Board.
"We are delighted to add an executive of Mr. Leonard's caliber to our board," said Paul Goddard, Ph.D., ARYx's chairman and chief executive officer. "Keith's depth of knowledge in commercial operations, combined with his extensive drug launch experience, will bring invaluable perspective to the team as we move toward commercialization of our product portfolio."
As senior vice president and general manager Amgen Europe, Leonard drove significant revenue and profitability growth for the company's commercial operations in Europe, Africa, and the Middle East. He expanded Amgen operations into 11 additional countries and oversaw numerous successful product launches. In his prior role as vice president for Amgen's rheumatology business unit, Leonard prepared the launch of arthritis drug Kineret in the U.S. and was responsible for the strategic process that led to Amgen's acquisition of Immunex and the addition of Enbrel to Amgen's rheumatology portfolio.
"ARYx is making vital contributions to medicine by addressing significant unsolved problems in drug safety and metabolism," said Mr. Leonard. "I look forward to bringing my commercial expertise to the many important drug development programs underway at the company."
Leonard replaces Klaus Veitinger, M.D., Ph.D., on ARYx's seven-member board of directors. In addition to Leonard, the members of ARYx's board include Paul Goddard, Ph.D., chairman and chief executive officer; Peter G. Milner, M.D., co-founder and president; Rob Adelman, M.D., principal, Orbimed Advisors; Lars Ekman, M.D., Ph.D., executive vice president and president, global R&D and corporate strategy, Elan Corporation; Nick Simon, M.B.A., general partner, MPM Bioventures III and managing director, Clarus Ventures; and Paul Sekhri, president and chief executive officer, Cerimon Pharmaceuticals.
About ARYx Therapeutics Inc.
ARYx Therapeutics is a privately-held pharmaceutical research and development company focused on treating significant medical needs unresolved by currently available therapies due to limitations in drug design and metabolism problems. By utilizing its innovative and integrated drug design strategies, ARYx targets known therapeutic mechanisms to create safer drugs. ARYx currently has three proprietary products in the clinic: ATI-7505, in Phase 2 for the treatment of gastrointestinal motility disorders such as GERD and gastroparesis; ATI-2042, in Phase 2 for the treatment of atrial fibrillation; and ATI-5923, an oral anticoagulant in Phase 1. For more information on the company, please see ARYx's Web site at http://www.aryx.com/.
CONTACT: David Nagler, Vice President, Corporate Affairs, of ARYx Therapeutics Inc., +1-510-585-2200, ext. 211; or Danielle Bertrand, +1-415-318-4247, or bertrand@Fleishman.com, for ARYx
Web site: http://www.aryx.com/